Metagenomi, Inc. Common Stock (MGX) - Total Assets
Based on the latest financial reports, Metagenomi, Inc. Common Stock (MGX) holds total assets worth $196.95 Million USD as of March 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Check MGX total capital reinvestment ratio to assess the company's total reinvestment commitment from operating cash flow.
Metagenomi, Inc. Common Stock - Total Assets Trend (2021–2025)
This chart illustrates how Metagenomi, Inc. Common Stock's total assets have evolved over time, based on quarterly financial data. Explore Metagenomi, Inc. Common Stock strategic investment ratio to see how much of total assets are deployed in long-term investments.
Metagenomi, Inc. Common Stock - Asset Composition Analysis
Current Asset Composition (September 2025)
Metagenomi, Inc. Common Stock's total assets of $196.95 Million consist of 74.9% current assets and 25.1% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 18.9% |
| Accounts Receivable | $305.00K | 0.1% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2021–2025)
This chart illustrates how Metagenomi, Inc. Common Stock's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see MGX stock market capitalisation.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Metagenomi, Inc. Common Stock's current assets represent 74.9% of total assets in 2025, a decrease from 76.7% in 2021.
- Cash Position: Cash and equivalents constituted 18.9% of total assets in 2025, down from 27.7% in 2021.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2021.
- Asset Diversification: The largest asset category is accounts receivable at 0.1% of total assets.
Metagenomi, Inc. Common Stock Competitors by Total Assets
Key competitors of Metagenomi, Inc. Common Stock based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
|
USA | $8.59 Billion |
|
Cyclacel Pharmaceuticals Inc
NASDAQ:CYCC
|
USA | $4.40K |
|
Krystal Biotech Inc
NASDAQ:KRYS
|
USA | $1.40 Billion |
|
Verona Pharma PLC ADR
NASDAQ:VRNA
|
USA | $572.87 Million |
|
Centessa Pharmaceuticals PLC ADR
NASDAQ:CNTA
|
USA | $641.76 Million |
|
Beijing Tiantan Biological Products Corp Ltd
SHG:600161
|
China | CN¥16.55 Billion |
|
Hebei Changshan Biochem Pharma
SHE:300255
|
China | CN¥4.66 Billion |
|
BB Biotech AG
SW:BION
|
Switzerland | CHF2.64 Billion |
Metagenomi, Inc. Common Stock - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 6.43 | 5.85 | 7.56 |
| Quick Ratio | 6.43 | 5.85 | 7.56 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $122.06 Million | $193.30 Million | $318.36 Million |
Metagenomi, Inc. Common Stock - Advanced Valuation Insights
This section examines the relationship between Metagenomi, Inc. Common Stock's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 0.34 |
| Latest Market Cap to Assets Ratio | 0.20 |
| Asset Growth Rate (YoY) | -31.9% |
| Total Assets | $221.10 Million |
| Market Capitalization | $44.42 Million USD |
Valuation Analysis
Below Book Valuation: The market values Metagenomi, Inc. Common Stock's assets below their book value (0.20x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: Metagenomi, Inc. Common Stock's assets decreased by 31.9% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Metagenomi, Inc. Common Stock (2021–2025)
The table below shows the annual total assets of Metagenomi, Inc. Common Stock from 2021 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-09-30 | $221.10 Million | -31.88% |
| 2024-09-30 | $324.60 Million | -11.03% |
| 2023-09-30 | $364.84 Million | -11.98% |
| 2022-09-30 | $414.49 Million | +191.91% |
| 2021-09-30 | $141.99 Million | -- |
About Metagenomi, Inc. Common Stock
Metagenomi Therapeutics, Inc. an in vivo genome editing company, develops curative genetic medicines in the United States. The company's lead development program, MGX-001, is designed to provide curative, life-long protection from bleeding events and joint damage in adults and children with hemophilia. It has a collaboration agreement with Ionis Pharmaceuticals, Inc. for apolipoprotein C-III for … Read more